Issues guidance following a transformative year with the Company adding two new business lines, significantly strengthening ...

UNIONDALE, NY / ACCESS Newswire / March 31, 2025 / Marquis Who's Who honors Lakshmi Prasad Bhatta for his outstanding ...

Fourth Quarter 2024 vs. Fourth Quarter 2023 Revenue of $21.8 million compared to $23.5 million;Gross profit of $4.3 million compared to $4.1 ...

Transformational 2024: successfully advanced from preclinical to clinical stage companyStrengthened leadership team to drive growth and advance ...

For the three months ended December 31, 2024, net income increased by 9.9% to $9,164,362 as compared to $8,335,525 for the same period in 2023. Net income for the year ended December 31, 2024 ...

To accelerate potential completion of ongoing partnership restructuring negotiations, Orchestra BioMed and Terumo have elected to enter a mediation process and are currently working on a procedural ...

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook ...

Quarterly Adjusted EBITDA of $1.9 Million in Q4, a $4.9 Million Improvement YoY Annual Adjusted EBITDA of $(0.2) Million in 2024, a $12.8 Million ...

Revenue reached $74.67M, exceeding guidance and demonstrating continued strong sales growth and execution ---- Net Income excluding ...

Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies. Other ...

Grew Total Revenue 8% Year-over-Year to $45 Million in the Fourth Quarter 2024 - - Assets Under Management (“AuM”) Increased 13% Year-over-Year ...

Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer Biomea preparing icovamenib for late-stage clinical development Multiple ...